<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31786154</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-6825</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>145</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of allergy and clinical immunology</Title>
          <ISOAbbreviation>J Allergy Clin Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.</ArticleTitle>
        <Pagination>
          <StartPage>877</StartPage>
          <EndPage>884</EndPage>
          <MedlinePgn>877-884</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2019.11.025</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0091-6749(19)31608-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Atopic dermatitis is a chronic inflammatory skin disease characterized by pruritic skin lesions.</AbstractText>
          <AbstractText Label="OBJECTIVE">We sought to evaluate the safety and efficacy of multiple doses of the selective Janus kinase 1 inhibitor upadacitinib in patients with moderate to severe atopic dermatitis.</AbstractText>
          <AbstractText Label="METHODS">In the 16-week, double-blind, placebo-controlled, parallel-group, dose-ranging portion of this 88-week trial in 8 countries (ClinicalTrials.gov, NCT02925117; ongoing, not recruiting), adults with moderate to severe disease and inadequate control by topical treatment were randomized 1:1:1:1, using an interactive response system and stratified geographically, to once-daily upadacitinib oral monotherapy 7.5, 15, or 30 mg or placebo. The primary end point was percentage improvement in Eczema Area and Severity Index from baseline at week 16. Efficacy was analyzed by intention-to-treat in all randomized patients. Safety was analyzed in all randomized patients who received study medication, based on actual treatment.</AbstractText>
          <AbstractText Label="RESULTS">Patients (N = 167) enrolled from November 21, 2016, to April 20, 2017. All were randomized and analyzed for efficacy (each upadacitinib group, n = 42; placebo, n = 41); 166 were analyzed for safety (each upadacitinib group, n = 42; placebo, n = 40). The mean (SE) primary efficacy end point was 39% (6.2%), 62% (6.1%), and 74% (6.1%) for the upadacitinib 7.5-, 15-, and 30-mg groups, respectively, versus 23% (6.4%) for placebo (P = .03, &lt;.001, and &lt;.001). Serious adverse events occurred in 4.8% (2 of 42), 2.4% (1 of 42), and 0% (0 of 42) of upadacitinib groups (vs 2.5% [1 of 40] for placebo).</AbstractText>
          <AbstractText Label="CONCLUSIONS">A dose-response relationship was observed for upadacitinib efficacy; the 30-mg once-daily dose showed the greatest clinical benefit. Dose-limiting toxicity was not observed.</AbstractText>
          <CopyrightInformation>Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guttman-Yassky</LastName>
            <ForeName>Emma</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: emma.guttman@mountsinai.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thaçi</LastName>
            <ForeName>Diamant</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Institute and Comprehensive Center Inflammation Medicine, University of Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pangan</LastName>
            <ForeName>Aileen L</ForeName>
            <Initials>AL</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Clinical Development, AbbVie Inc, North Chicago, Ill.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hong</LastName>
            <ForeName>H Chih-Ho</ForeName>
            <Initials>HC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Skin Science, University of British Columbia and Probity Medical Research, Surrey, British Columbia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Papp</LastName>
            <ForeName>Kim A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Probity Medical Research and K Papp Clinical Research, Waterloo, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reich</LastName>
            <ForeName>Kristian</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation Center, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beck</LastName>
            <ForeName>Lisa A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University of Rochester Medical Center, Rochester, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mohamed</LastName>
            <ForeName>Mohamed-Eslam F</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology and Pharmacometrics, AbbVie Inc, North Chicago, Ill.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Othman</LastName>
            <ForeName>Ahmed A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology and Pharmacometrics, AbbVie Inc, North Chicago, Ill.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anderson</LastName>
            <ForeName>Jaclyn K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Clinical Development, AbbVie Inc, North Chicago, Ill.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Yihua</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Data and Statistical Sciences, AbbVie Inc, North Chicago, Ill.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teixeira</LastName>
            <ForeName>Henrique D</ForeName>
            <Initials>HD</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Clinical Development, AbbVie Inc, North Chicago, Ill.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silverberg</LastName>
            <ForeName>Jonathan I</ForeName>
            <Initials>JI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02925117</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Allergy Clin Immunol</MedlineTA>
        <NlmUniqueID>1275002</NlmUniqueID>
        <ISSNLinking>0091-6749</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4RA0KN46E0</RegistryNumber>
          <NameOfSubstance UI="C000613732">upadacitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003876" MajorTopicYN="N">Dermatitis, Atopic</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000075242" MajorTopicYN="N">Janus Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Atopic dermatitis</Keyword>
        <Keyword MajorTopicYN="Y">Janus kinase</Keyword>
        <Keyword MajorTopicYN="Y">eczema</Keyword>
        <Keyword MajorTopicYN="Y">efficacy</Keyword>
        <Keyword MajorTopicYN="Y">placebo-controlled</Keyword>
        <Keyword MajorTopicYN="Y">randomized clinical trial</Keyword>
        <Keyword MajorTopicYN="Y">safety</Keyword>
        <Keyword MajorTopicYN="Y">upadacitinib</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31786154</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jaci.2019.11.025</ArticleId>
        <ArticleId IdType="pii">S0091-6749(19)31608-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
